Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V-FAST: CPX-351 combinations in newly diagnosed AML
NCT04075747Phase 1Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Dec 2019
- Primary completion
- Feb 2022
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label trial of daunorubicin + cytarabine liposome in acute myeloid leukemia (AML) (3 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Recommended Phase 2 Dose up to 30 months and Incidence of Adverse Events and Dose Limiting Toxicities up to 30 months. Started Dec 2019; status: completed.
02
Drugs
daunorubicin + cytarabine liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04075747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04075747.